Journal Articles

Donald and Barbara Zucker School of Medicine
Academic Works

2014

CB2 Receptor Deficiency Increases Amyloid
Pathology and Alters Tau Processing in a
Transgenic Mouse Model of Alzheimer's Disease
Jeremy Koppel
Hofstra Northwell School of Medicine

V. Vingtdeux
Northwell Researcher

P. Marambaud
Northwell Researcher

C. d'Abramo
Northwell Researcher

H. Jimenez
Northwell Researcher
See next page for additional authors

Follow this and additional works at: https://academicworks.medicine.hofstra.edu/articles
Part of the Medical Molecular Biology Commons, and the Psychiatry Commons
Recommended Citation
Koppel J, Vingtdeux V, Marambaud P, d'Abramo C, Jimenez H, Stauber M, Friedman R, Davies P. CB2 Receptor Deficiency Increases
Amyloid Pathology and Alters Tau Processing in a Transgenic Mouse Model of Alzheimer's Disease. . 2014 Jan 01; 20():Article 1059 [
p.]. Available from: https://academicworks.medicine.hofstra.edu/articles/1059. Free full text article.

This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic Works. It has been accepted for
inclusion in Journal Articles by an authorized administrator of Donald and Barbara Zucker School of Medicine Academic Works.

Authors

Jeremy Koppel, V. Vingtdeux, P. Marambaud, C. d'Abramo, H. Jimenez, M. Stauber, R. Friedman, and P.
Davies

This article is available at Donald and Barbara Zucker School of Medicine Academic Works:
https://academicworks.medicine.hofstra.edu/articles/1059

CB2 Receptor Deficiency Increases Amyloid Pathology and
Alters Tau Processing in a Transgenic Mouse Model of
Alzheimer’s Disease
Jeremy Koppel,1 Valerie Vingtdeux,1 Philippe Marambaud,1 Cristina d’Abramo,1 Heidy Jimenez,1
Mark Stauber,2 Rachel Friedman,3 and Peter Davies1
1

Litwin-Zucker Research Center, Feinstein Institute for Medical Research, North-Shore Long Island Jewish Health System, Manhasset,
New York, United States of America; 2Yeshiva University, New York, New York, United States of America; and 3Queens College, New
York, New York, United States of America

The endocannabinoid CB2 receptor system has been implicated in the neuropathology of Alzheimer’s disease (AD). In order to
investigate the impact of the CB2 receptor system on AD pathology, a colony of mice with a deleted CB2 receptor gene, CNR2,
was established on a transgenic human mutant APP background for pathological comparison with CB2 receptor–sufficient transgenic mice. J20 APP (PDGFB-APPSwInd) mice were bred over two generations with CNR2 –/– (Cnr2 tm1Dgen/J) mice to produce a
colony of J20 CNR2 +/+ and J20 CNR2 –/– mice. Seventeen J20 CNR2 +/+ mice (12 females, 5 males) and 16 J20 CNR2 –/– mice (11 females, 5 males) were killed at 12 months, and their brains were interrogated for AD-related pathology with both biochemistry and
immunocytochemistry (ICC). In addition to amyloid-dependent endpoints such as soluble Aβ production and plaque deposition
quantified with 6E10 staining, the effect of CB2 receptor deletion on total soluble mouse tau production was assayed by using a
recently developed high-sensitivity assay. Results revealed that soluble Aβ42 and plaque deposition were significantly increased
in J20 CNR2 –/– mice relative to CNR2 +/+ mice. Microgliosis, quantified with ionized calcium-binding adapter molecule 1 (Iba-1)
staining, did not differ between groups, whereas plaque associated microglia was more abundant in J20 CNR2 –/– mice. Total tau
was significantly suppressed in J20 CNR2 –/– mice relative to J20 CNR2 +/+ mice. The results confirm the constitutive role of the CB2
receptor system both in reducing amyloid plaque pathology in AD and also support tehpotential of cannabinoid therapies targeting CB2 to reduce Aβ; however, the results suggest that interventions may have a divergent effect on tau pathology.
Online address: http://www.molmed.org
doi: 10.2119/molmed.2013.00140.revised

INTRODUCTION
The primary neuropathological hallmarks of Alzheimer’s disease (AD) comprise amyloid-β (Aβ) deposits and neurofibrillary tangles composed of
abnormally phosphorylated tau protein
in the brain parenchyma (1). Deposition
of Aβ in brain is known to induce microgliosis (2) and attendant cytokine production (3), events believed to be important drivers of the pathogenic cascade

(4). There is a gathering interest in the
potential utility of cannabinoid interventions for the prevention or treatment of
AD pathology, predicated on both the robust immune response evidenced in AD
pathology and the utility of cannabinoids
in dampening inflammatory pathways.
The endocannabinoid system comprises at least two biolipid signaling molecules produced on demand in a wide
spectrum of cell types and tissues, in-
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cluding neurons and immune cells of the
central nervous system, that bind to at
least two cannabinoid receptors, CB1 and
CB2 (5). The CB2 receptor is expressed
primarily in immune-competent cells
and functions as a feedback inhibitor of
inflammatory cytokine production (6).
There is evidence that perturbations in
the endocannabinoid system may be either a risk factor for or a biomarker of
AD. In a discovery-based gene expression experiment using microarray, CNR2,
the gene encoding the CB2 receptor, was
one of a select group of genes (from
Gene Chip of approximately 45,000
genes) identified as having increased expression in AD brain compared with agematched control brains (7). This study
was followed by an investigation of
mRNA expression in the blood of subjects with AD in which expression of

MOL MED 20:29-36, 2014 | KOPPEL ET AL. | 29

CB2 RECEPTOR DEFICIENCY IN AN AMYLOID MOUSE MODEL

CNR2 was associated with AD and correlated with measures of cognitive impairment (8). More recently, a study of
mRNA expression and epigenic regulation of endocannabinoid system components in the periphery of AD patients relative to controls revealed an increase in
the endocannabinoid-degrading enzyme
fatty acid amide hydrolase (FAAH), an
increase in FAAH protein levels, an increase in FAAH activity and a reduction
in DNA methylation at the FAAH gene
promoter (9).
Neuropathological evidence supports
the involvement of the CB2 receptor in
plaque pathology of AD. Evidence of the
involvement of this receptor in disease
pathology emerged from a study in
which selective expression of the receptor in neuritic plaque-associated microglia was demonstrated in regions implicated early in disease progression
(hippocampus and entorhinal cortices) in
AD patients (10). Recently, increased receptor expression in frontal cortex (Brodmann area 10) of AD patients with more
advanced disease (Braak stage V/VI)
was found to correlate with amyloid
(Aβ) levels and plaque density score (11).
The localization of CB2 receptor–positive
microglia in regions of human AD
pathology contextualized within the role
of the immune cell–expressed CB2 receptor as a feedback inhibitor of immune responsiveness suggests a participatory
role for this receptor system in the inflammatory pathology of AD and the potential for a novel target for intervention.
Promising in vitro studies investigating
cellular and pathological models have
gradually given way to direct in vivo experiments focused on cannabinoid therapeutics for the interruption of the Aβ
deposition cascade of AD.
CB2 receptor stimulation in AD as a viable strategy for preventing Aβ-induced
microglial activation and ameliorating
cognitive impairment was first demonstrated in a nontransgenic animal model
of AD (12). In this experiment, intracerebroventricular injections of Aβ or control
peptide were administered to mice with
and without a cannabinoid. As expected,

activated microglia were observed in the
cortex of Aβ-treated mice. It was demonstrated that cannabinoid treatment with
Aβ prevented microglial activation and
that although Aβ-treated mice manifested very typical AD model impairments of spatial navigation, the cannabinoid prevented this Aβ-induced
cognitive impairment. Recently, investigators exposed 11-month-old transgene
amyloid precusor protein (TgAPP) 2576
mice to prolonged treatment with a synthetic CB2 receptor agonist, JWH-133
(13). When compared with vehicletreated mice, JWH-133 treatment reduced
microgliosis, decreased soluble Aβ40 and
Aβ42 and enhanced glucose metabolism
in the hippocampus and cortical regions,
suggesting that targeting the microglial
CB2 receptor interrupts critical events in
the amyloid cascade via a direct impact
on microglial activation. A subsequent
investigation with the same compound
in APP/presenilin 1 (PS1) mice revealed
that treatment induced cognitive improvement, as well as reduced expression of the proinflammatory cytokines
interleukin (IL)-1β, IL-6, tumor necrosis
factor (TNF)-α, and interferon (IFN)-γ
(14). Recently, a novel CB2 agonist
(MDA7) was shown to promote Aβ clearance, decrease IL-1β and improve memory in rats with cognitive impairment induced by bilateral microinjections of Aβ
into the hippocampus (15).
Beyond the impact on Aβ, cannabinoid interventions may influence tau
processing, mediated by inflammatory
pathways. Emerging evidence suggests
that neuroinflammation may be a critical event in tangle production (16).
From the perspective of cellular pathology, activated microglia have long been
known to be spatially associated with
tangle pathology (17). In a recent study,
it was demonstrated that glial responses correlate positively with tangle
burden and are more likely to be found
in the vicinity of tangles (18). Relationships between inflammation and alterations in the processing of tau proteins
have been suggested. Activated microglia cultured with cortical neurons
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induce tau phosphorylation, mediated
by p38 mitogen–activated protein kinase pathways (19). In a mouse model
expressing P301S-mutated tau, microglial activation preceded tangle formation, suggesting that inflammation
may drive intraneuronal changes in tau
processing (20). Lipopolysaccharide injection into the brains of mice expressing human mutant tau induces microglial activation and phosphorylation
of tau (21,22). These data suggest that
targeted interruption of inflammatory
pathways in the absence of amyloid
with cannabinoid therapies may influence tau processing and potentially tangle production.
To investigate in what way the CB2 receptor is involved in AD pathogenesis,
we designed an experiment to determine
whether knocking out the CB2 receptor
influences Aβ production, plaque deposition or related pathologies in APP transgenic mice. To this end, we established a
colony of mice with a deleted CB2 receptor gene (CNR2) on a transgenic human
mutant APP background for pathological
comparison with CB2 receptor sufficient
transgenic mice. In addition to Aβdependent endpoints, the effect of CB2
receptor deletion on total soluble mouse
tau production and hyperphosphorylated tau (at a conformational changing
epitope [Ser396/404] known to be a principal component of neurofibrillary tangles) were assayed by using a recently
developed high-sensitivity assay created
in our laboratory (23).
MATERIALS AND METHODS
Animals
CB2 receptor knockout mice
(CNR2–/–). The Cnr2tm1Dgen/J knockout
mouse was developed by homologous
recombination resulting in a 334–base
pair deletion in the coding exon of the
CNR2 gene, with a neomycin gene insertion germinated in a C57/BL6 mouse.
Macrophages from homozygous mutant
mice lacking the CB2 receptor are resistant to the inhibitory effects of δ-9
tetrahydrocannabinol (24). Beyond alope-
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cia, there are no other reported phenotypic aberrations in these mice (25). Consistent with the effects of the CB2 system
on immune modulation, CNR2–/– mice
have been reported to exhibit more severe experimental autoimmune encephalitis than wild-type mice as well as
enhanced allergic responses (26,27). It
has been previously demonstrated that
CNR2–/– mice expressing the human mutant Huntington exon 1 (R6/2 mice) have
increased microglial activation (detected
via immunostaining with ionized
calcium-binding adapter molecule 1
[Iba-1] antibody) and exacerbated disease progression when compared with
CNR2+/+ R6/2 mice (28).
Transgenic amyloid mice (J20). The
J20 mouse expresses a mutant form of
the amyloid precursor protein bearing
the K670N/M671L and V717F mutations
inserted via the human platelet–derived
growth factor β polypeptide promoter
into C57/BL6 × DBA/2 F2 one-cell embryos; hemizygous mice express transgene product in cerebral neurons, especially the neocortex and hippocampus
(29). At 5 months of age, diffuse Aβ deposition in the dentate gyrus and neocortex is first evident. Plaques are evident in
50% of J20 mice by 7 months and nearly
100% of mice by 8 months and demonstrate a significant reactive microgliosis
(29,30).
J20 CNR2–/– mice. The goal of the present study was to establish a colony of
transgenic amyloid mice lacking the CB2
receptor for comparison with transgenic
amyloid mice with an intact CB2 receptor
system (J20 CNR2–/– and J20 CNR2+/+).
To create a strain of J20 CNR2–/– mice, J20
mice were backcrossed with J20 CNR2–/–
mice over two generations, first producing a generation of J20 CNR2+/– mice,
then J20 CNR2–/– mice. Mice were gender
matched and raised to 1 year before
being euthanized. All animal experiments
were performed according to procedures
approved by the Feinstein Institute for
Medical Research Institutional Animal
Care and Use Committee. CNR2 knockout (strain name B6.129P2-Cnr2tm1Dgen/J)
mice and TgAPP [strain name B6.Cg-

Tg(PDGFB-APPSwInd)20Lms/2Mmjax,
also known as “J20”] transgenic mice,
both on a C57BL/6 background, were obtained from The Jackson Laboratory (Bar
Harbor, ME, USA).
Genotyping
Genotyping was performed at
Transnetyx (Cordova, TN, USA) from
tail samples, by using a quantitative
polymerase chain reaction (qPCR)-based
system to detect the presence or absence
of a target sequence within each sample.
The APP probe was targeted to the
human cDNA exon–exon junction sequence and detects the presence of that
transgene within a sample. The CNR2
probe was targeted to a sequence in the
disrupted CNR2 gene and detects the
presence of a neomycin cassette within
each sample. J20 CNR2+/+, J20 CNR2–/–,
CNR2–/– and wild-type (WT) mice were
group-housed (three to five animals per
cage) with a 12:12-h light/dark cycle
and with ad libitum access to water and
food. At 52 wks of age (12 months),
mice were killed. Brains were hemidissected, and one hemibrain was fixed
with 4% paraformaldehyde in 0.1 molar
phosphate-buffered saline (pH 7.6),
whereas the other hemibrain was sequentially extracted, as described in
previously published protocols (31).
Paraformaldehyde-fixed brain hemispheres were dehydrated in ethanol,
paraffin-embedded and cut with a microtome into 5-μm sagittal sections.
Enzyme-Linked Immunosorbent
Assay: Aβ, DA31 and PHF1 Levels
Hemisectioned brains were homogenized and sonicated in Tris-buffered
saline containing 2% sodium dodecyl sulfate (SDS) and 1× cOmplete protease inhibitor mixture (Roche Applied Science,
Indianapolis, IN, USA) and centrifuged at
100,000g for 1 h at 4°C. The supernatant
was then removed, and the resulting pellet was extracted with 70% formic acid in
water. The 2% SDS extracts were diluted
1:40. Formic acid extracts were neutralized initially by a 1:20 dilution into
1 mmol/L Tris phosphate buffer (pH 11)

and then diluted as necessary to normalize protein concentration. Brain Aβ40 and
Aβ42 were quantified using an enzymelinked immunosorbent assay (ELISA) kit
following the manufacturer’s instructions
[Human β Amyloid (1-40) ELISA Kit (cat.
no. 292-62301) and Human β Amyloid
(1-42) ELISA Kit (cat. no. 298-62401);
Wako, Richmond, VA, USA]. ELISA
plates were read on a Tecan GENios Pro
reader (Tecan Group Ltd., Männedorf,
Switzerland) at 450 nmol/L. Low-tau
sandwich ELISA was performed to detect
total tau (DA31) and pSer396/404 (PHF1)
levels. Briefly, 96-well plates were coated
with DA31 (or PHF1 at a final concentration of 6 μg/mL for 48 h at 4°C). After
washing and blocking, 50 μL of each sample was added in duplicate, using the
proper dilution in 20% SuperBlock
(Thermo Scientific, part of Thermo Fisher
Scientific Inc., Waltham, MA, USA):
1:10,000 for the DA31 ELISA (antibodycoated plates provided by P Davies), and
1:5,000 for the PHF1 ELISA (antibodycoated plates provided by P Davies), respectively. At the same time, 50 μL DA9HRP detection antibody was added to the
wells and tapped to combine. Plates were
incubated overnight by shaking at 4°C.
After washing, the 1-Step ULTRA TMBELISA substrate (Thermo Scientific) was
added for 30 min at room temperature
and then blocked with 2 mol/L sulfuric
acid. Plates were read with an Infinite
m200 plate reader (Tecan) at 450 nmol/L.
The measured values were normalized
according to the protein concentration.
Immunocytochemistry (ICC)
All ICC analysis took place in triplicate; three paraffin-embedded sections
were selected from each mouse for each
antibody representing equally staggered
sagittal cutting intervals. For Αβ staining,
sections were processed according to previously published protocols (32). Briefly,
sections were pretreated with 70% formic
acid for 15 min and immersed in 1%
H2O2 for 30 min. Sections were then incubated with 5% milk in Tris-buffered
saline for 1 h and with 6E10 primary antibody (1:1,000 dilution; Covance Inc.,
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Princeton, NJ, USA) overnight at 4°C. Incubation with biotin-labeled goat antimouse IgG1 secondary antibodies (1:1,000
dilution; SouthernBiotech, Birmingham,
AL, USA) was performed before incubation with streptavidin-horseradish peroxidase (SouthernBiotech) and diaminobenzidine tetrahydrochloride. For microglial
staining, sections were first pretreated
with Dako Target Retrieval Solution at
95°C for 30 min and then processed with
a similar protocol by using the Iba-1 primary antibody (1:1,000 dilution; Wako),
followed by biotin-labeled goat anti-rabbit secondary antibody (1:1,000 dilution;
SouthernBiotech). Sections were observed
with a light microscope, and pictures
were generated by using an Olympus 5
megapixel camera (Olympus Corporation
of the Americas, Center Valley, PA, USA).
Image analysis for quantification of ICC
(staining density) used grayscale thresholding and pixel estimation/conversion
to percent area stained with ImageJ software (NIH, Bethesda, MD, USA; http://
imagej.nih.gov/ij), following previously
described techniques (33). Percent area
stained was then averaged for sections analyzed in triplicate from each mouse and
compared by group (J20 CNR2+/+ versus
J20 CNR2–/–). For cellular quantification of
plaque-associated microglia, with Iba-1
staining, two representative plaques were
selected from each mouse; plaques were
identified by the characteristic clustering
of reactive microglia in a circular profile,
defining the circumference of the plaque.
Iba-1-positive microglia were counted
along the circumference of the plaques
and then compared by group.
Statistical Analysis
Between-group statistical analyses
were performed with unpaired Student
t tests for differences between two-group
means, and analysis of variance
(ANOVA) where appropriate, by using
GraphPad Prism Software (GraphPad
Software Inc., La Jolla, CA, USA).
RESULTS
To evaluate the impact of the CB2 receptor on amyloid pathology, microglio-

sis and tau processing, a colony of J20
CNR2+/+ and J20 CNR2–/– mice was established. A total of 17 J20 CNR2+/+ mice
(12 female, 5 male) and 16 J20 CNR2–/–
mice (11 female, 5 male) were euthanize
after 1 year, and brain sections were
taken for immunohistochemistry and
biochemistry. The duration of the study
was set at 1 year, to allow ample time for
plaque production and microgliosis,
while avoiding loss of mice from age-related mortality issues in the transgenic
model. Because there have been reports
of amyloid production being influenced
by gender in transgenic models (34), the
groups were matched for gender (one female J20 CNR2–/– mouse died before the
1-year time point).
Our approach involved a combination
of biochemistry interrogating levels of soluble Aβ40 and Aβ42, and immunohistochemistry for quantification of plaque
pathology. Previous experiments have
demonstrated that CB2 receptor stimulation in cell culture promotes successful
phagocytosis of the Aβ42 peptide, the
chief component of plaque pathology (35).
This result would suggest that the absence of the receptor system would drive
increases in Aβ42 and plaque pathology.
When AD brains are compared with controls, both levels of soluble and insoluble
(aggregated, plaque associated) Aβ increase, but there is a shift from soluble
forms to insoluble forms such that, in AD,
insoluble Aβ dominates the total fraction
of amyloid in the brain, whereas in
healthy controls, soluble forms predominate (36). CB2 receptor–mediated reduction in Aβ levels in J20 CNR2+/+ mice, mediated by phagocytosis of organized
plaque, was predicted to be primarily evident in plaque size, with a secondary effect on soluble Aβ species as reservoirs of
Aβ drop.
The J20 CNR2+/+ and J20 CNR2–/– mice
differed primarily on immunohistochemical measurements of plaque pathology,
with a smaller impact on soluble Aβ
species. Plaque staining density assessed
by ICC differed between groups, reflecting
increased deposition in the hippocampus
(Figure 1A–C), anterior cortex (Figure 1D)
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and posterior cortex (Figure 1E) of J20
CNR2–/– mice. This result is consistent
with the expectation that any increase in
pathology in J20 CNR2–/– mice would be
driven by impaired microglial phagocytic
reduction of plaques. The biochemical
analysis, using ELISA to evaluate soluble
forms, revealed that while soluble Aβ42
was significantly increased in CNR2deficient mice (Figure 2B), soluble Aβ40
did not differ significantly between groups
(Figure 2A). Because Aβ42– rather than the
more common Aβ40– is known to be the
more fibrillogenic isoform, the reported elevation is consistent with the evident increase in plaque pathology (37).
An increased microglial response was
anticipated in J20 CNR2–/– mice. It has
been demonstrated that the CB2 receptor
stimulation has an immunosuppressive
effect (38,39), blocking the production of
proinflammatory cytokines (40) and that
simulation of the CB2 receptor inhibits
microglial activation. Direct CB2 receptor
stimulation has been shown to prevent
Aβ-induced microglial activation in an
animal model of AD and improves cognitive outcomes, highlighting the negative
consequence of microglial response in
amyloid models (12). Mice lacking the
CB2 receptor, deficient in the feedback inhibition of microglial activation that the
receptor provides, would be expected
under conditions of Aβ plaque deposition
to evidence a higher density of microglial
representation. To quantify microglial activation, our approach used immunohistochemical analysis of tissue with the microglial marker Iba-1. Iba-1 is a protein
that is specifically expressed by
macrophages and microglia and is upregulated under conditions of activation
(41). Microgliosis, quantified with immunohistochemistry (Iba-1) staining density did not, contrary to expectation, differ significantly between J20 CNR2–/– and
J20 CNR2+/+ mice (Figure 3A). However,
plaque-associated microglia (a more local
barometer of Aβ plaque–driven inflammation) were significantly more prominent in J20 CNR2–/– mice (Figure 3B).
To explore the relationship between
microglial-driven alterations in amyloid
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Figure 1. (A, B) Representative sections at 4× magnification reflecting ICC staining sample
means in mouse hippocampus (A: J20 CNR2+/+; B: J20 CNR2–/–). (C) Quantification of
human amyloid ICC staining in mouse hippocampus using 6E10 monoclonal antibodies.
Data are means and 95% confidence intervals. (D) Quantification of human amyloid ICC
staining in anterior mouse cortex using 6E10 monoclonal antibodies. Data are means and
95% confidence intervals. (E) Quantification of human amyloid ICC staining in posterior
J20 mouse cortex with 6E10 monoclonal antibody. Data are means and 95% confidence
intervals. *p < 0.05.

Figure 2. (A) Quantification of soluble Aβ40 in hemisectioned brains of CB2-deficient versus CB2-sufficient mice. Data are means. (B) Quantification of soluble Aβ42 in hemisectioned brains of CB2-deficient versus CB2-sufficient mice. Data are means and 95% confidence intervals). *p < 0.05.

deposition and tau pathology in the J20
mouse, total soluble mouse tau (assayed
with DA31) ELISA and Ser396/404
phospho-tau (assayed with PHF1 ELISA)
were compared between the J20 CNR2–/–
mouse and the J20 CNR2+/+ mouse. Total
tau was significantly reduced in J20
CNR2–/– mice (Figure 4A). A recent review of experimental manipulations of
microglia in amyloid mouse models has
reported that in published studies evaluating both amyloid and tau outcomes,
changing the state of microglial activation has inverse effects on amyloid and
tau pathology; experimental interventions that drive amyloid down as a function of microglial activity and phagocytosis (for instance, deletion of the
fractalkine receptor, or the administration of LPS) increases tau pathology (42).
The pathways connecting proinflammatory reduction of amyloid and tau exacerbation are not as yet clear. However,
because experimentally enhancing microgial phagocytosis of amyloid may drive
tau pathology, perhaps via factors released by the microglia themselves in response to these manipulations and not as
the result of amyloid (42), it may be that
the deletion of the microglial CB2 receptor in the context of amyloid-driven microglial activation reduces tau.
Like other APP transgenic mouse models, J20 mice do not develop neurofibrillary tangle pathology. A previous study
reported, however, that in the cortex and
hippocampus of aged TgCRND8 amyloid
mice, tau is hyperphosphorylated at the
Ser396/404 epitope known to be a principal component of neurofibrillary tangles
(43). To date, no studies have used ELISA
to quantify soluble total tau and
Ser396/404 phospho-tau in J20 mice. Our
approach used ELISA because it has an
advantage over Western blot and immunohistochemical approaches in its
ability to give an exact quantification of
protein concentration. Because there is no
aggregated tau-forming neurofibrillary
tangle pathology in transgenic amyloid
mice such as the J20, most of the tau
would be anticipated to be present in soluble form, making the soluble tau ELISA
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Figure 3. (A) Quantification of ICC Iba-1 staining in mouse hippocampus using Iba-1 monoclonal antibody. Data are means (no significant differences observed). (B) Quantification
of plaque-associated microglia with Iba-1 in mouse hippocampus. Data are means and
95% confidence intervals. (C) Representative sections at 40× magnification reflecting average plaque-associated microgliosis in mouse hippocampus. *p < 0.05.

a sensitive approach. A previous study
has demonstrated an inhibitory effect of
CB2 receptor stimulation with JWH-133
on several tau kinases, including GSK3β,
in an amyloid mouse model of AD, and a
reduction in one phospho-tau epitope not
investigated in the current study (14). For
this reaseon, we anticipated elevations of
soluble Ser396/404 phospho-tau in J20
CNR2–/– mice. However, levels of
Ser396/404 phospho-tau were reduced in
the J20 mouse relative to controls and in
J20 CNR2–/– mice (Figure 4B). Of note,
the JWH-133 stimulation reported (14)
did not result in any modification in Aβ
plaque deposition, a condition different
from the current report. As noted above,
microglial conditions that drive changes
in amyloid may have a different impact
on tau processing than conditions that do
not. Because total tau was reduced in the
J20 CNR2–/– mouse (as discussed above),
and because DA31 includes all tau protein (even phosphorylated tau), we evaluated the ratio of Ser396/404 to total tau to
evaluate the relative proportion of this
pathogenic species represented in total
tau. The ratio of Ser396/404 to total tau
was decreased only in J20 CNR2+/+ mice
relative to J20 CNR2–/– mice and controls
(Figure 4C). This result suggests that in
the J20 mice, there may be a shift in the
relative activity of tau kinases, with a reduction in the kinases responsible for
phosphorylating Ser396/404. The J20

CNR2–/– mouse, however, had an increase in the ratio of Ser396/404 phoshotau to total tau when compared with the
J20 CNR2+/+ mouse. It may be that in the
J20 CNR2–/– mouse, the mechanism responsible for the relative reduction of
total tau precedes kinase-driven phosphorylation, such that there is a relative
elevation of the Ser396/404 ratio in the
J20 CNR2–/– mouse relative to the J20
CNR2+/+ mouse (Figure 4C) that does not
reflect any difference in the activity of the
responsible tau kinase. It is also possible
that as CB2 receptor stimulation has been
shown to reduce the activity of tau kinases and lower tau phosphorylation
(14), there is a relative increase in kinase
activity in CB2-deficient mice compensating for the reduction in the J20 mouse.

DISCUSSION
The flourish of recent reports of the role
of the CB2 receptor in AD (11) and of the
CB2 receptor manipulation in mouse
models of AD (13–15) suggest that the
field of AD therapeutics is moving toward
experimental cannabinoid interventions
in humans, perhaps targeting the CB2 receptor. Of note, each of these studies focused on amyloid models of disease, and
only one study included tau outcomes
(14). Although the results of the tau-outcome experiment suggest a salutary effect
on phosphorylated tau via CB2 receptor
stimulation, the study only looked at one
phosphorylation epitope (Thr181), and
only quantified via immunofluorescent
staining in the regions of plaques, and not
throughout the cortex. Given the potential
exacerbation of tau pathology achieved
via microglial-targeted reduction of amyloid, including tau outcomes in amyloid
models is important in evaluating the
risks and benefits of moving forward with
human trials (42).
Although previous studies have evaluated changes in plaque deposition in response to manipulations of the CB2 receptor, no previous studies have
evaluated the constitutive role of the CB2
receptor in reducing plaque deposition;
the production of a transgenic APP/CB2
knockout mouse afforded the opportunity to evaluate the role of the microglial
CB2 receptor without pharmacological
intervention. J20 CNR2–/– mice had increased plaque pathology in the hip-

Figure 4. (A) Quantification of soluble DA31 in hemisectioned brains of mice. Data are
means and 95% confidence intervals. (B) Quantification of PHF1 in hemisectioned brains
of mice. Data are means and 95% confidence intervals. (C) PHF1/DA31 ratio. *p < 0.05.
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pocampus, anterior cortex and posterior
cortex. This result is consistent with one
previous report (13) demonstrating the
efficacy of oral canabinoid administration in reducing Aβ, although a subsequent study looking at a different compound found an improvement in
cognition putatively mediated by microglial manipulation without alterations
in levels of Aβ (14). While there was an
increase in soluble, nonaggregated Aβ42
in the J20 CNR2–/– mouse, and while the
mean levels of soluble Aβ40 were higher
in the J20 CNR2–/–, elevations in Aβ40
did not reach statistical significance. A
larger sample size may have yielded different results.
It was anticipated that CB2 receptor
deletion in the J20 mouse would result in
an upregulation of microglial activation
and that the CB2 receptor would enhance
microglial chemotaxis, driven primarily
by Aβ, via an endocannabinoid concentration gradient to the regions of plaque,
such that, in knockout mice, there would
be less plaque-associated microglia (44).
Although we did find an increase in
plaque burden in CB2 receptor–deficient
mice, we had anticipated a broader microglial response reflected in increased
Iba-1 staining. This result was suggested
by a previous experiment in which CB2
receptor stimulation reduced Iba-1positive microglia in TgAPP mice by
>50% (13). It may be that downregulation of microglial response occurs only
locally to plaques, in regions of increased
endocannabinoid production; this is consistent with our finding of decreased
plaque-associated microglia in CB2
receptor–sufficient mice. Although it is
conceivable that microglial phagocytosis
of plaque is enhanced by the activation of
the CB2 receptor, it is also possible that
this is observed only in the context of exogenous, rather than endogenous, stimulation. The reported results challenge the
notion that the CB2 receptor, in the absence of exogenous stimulation, enhances
chemotaxis of microglia to regions of
plaque deposition, since receptordeficient mice had more plaque-associated
microglia. The enhanced presence of

plaque-associated microglia in receptordeficient mice together with enhanced
plaque deposition also challenges the
notion that increased recruitment of
microglia to regions of plaque necessarily
results in an augmentation of plaque clearance and suggests that microglial phagocytosis of Aβ in CB2 receptor–deficient
mice may be relatively impaired. The
specific advantage of CB2 receptor stimulation in successful phagocytosis of Aβ42
fragments has been previously demonstrated in vitro and, in the context of these
results, underscores the need for further
in vitro studies evaluating the potential
negative impact of microglial CB2 receptor deficiency on phagocytosis (45).

targeted interventions that reduce Aβ
deposition may have altered tau proteins
in undesirable directions.

CONCLUSION
The reported diminution of total tau in
the J20 CNR2–/– mouse in the context of
elevations in Aβ is consistent with previous studies evaluating the impact of
proinflammatory manipulations of microglia in amyloid mouse models, in
which Aβ reductions were associated
with increases in tau (42). In the absence
of microglial manipulation, and in studies of tau mutants, levels of Aβ and tau
have been more correlative. For instance,
in one study of the TgCRND8 APP
mouse, aged mice were found to have increased PHF1 immunoreactivity by Western blot relative to wild-type mice (43).
Total tau proteins did not differ between
TgCRND8 mice and nontransgenic agematched controls. In studies of amyloid
immune therapy in 3xTg-AD mice (that
incorporate both amyloid and tau mutations), reductions in amyloid were also
coupled with proteasome-dependent reductions in tau, including total soluble
tau measured with ELISA (46,47). Although the relationship between Aβ deposition and tau production is complex,
and experiments using different models
may show relationships between these
pathogenic proteins in different directions, it is clear that incorporating both
Aβ and tau outcomes is critical to anticipate what may happen in experimental
trials of human disease. The current report suggests that cannabinoid CB2-
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